Using a vancomycin PBPK model in special populations to elucidate case-based clinical PK observations.

about

Using a vancomycin PBPK model in special populations to elucidate case-based clinical PK observations.

Item

http://www.wikidata.org/entity/Q49989644

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Using a vancomycin PBPK model ...... ased clinical PK observations.

@en

Using a vancomycin PBPK model ...... ased clinical PK observations.

@nl

type

Item

label

Using a vancomycin PBPK model ...... ased clinical PK observations.

@en

Using a vancomycin PBPK model ...... ased clinical PK observations.

@nl

prefLabel

Using a vancomycin PBPK model ...... ased clinical PK observations.

@en

Using a vancomycin PBPK model ...... ased clinical PK observations.

@nl

P1476

Using a vancomycin PBPK model ...... ased clinical PK observations.

@en

P2093

Brooks T McPhail

http://www.w3.org/2001/XMLSchema#string

Trevor N Johnson

http://www.w3.org/2001/XMLSchema#string

Tsuyoshi Fukuda

http://www.w3.org/2001/XMLSchema#string

P2860

Optimizing the Clinical Use of Vancomycin

The Simcyp population-based ADME simulator

A re-evaluation and validation of ontogeny functions for cytochrome P450 1A2 and 3A4 based on in vivo data.

Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver.

A semi-mechanistic model to predict the effects of liver cirrhosis on drug clearance.

Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children.

The simcyp population based simulator: architecture, implementation, and quality assurance.

Study of the molecular mechanism of decreased liver synthesis of albumin in inflammation

Pharmacokinetics and serum bactericidal activity of vancomycin alone and in combination with ceftazidime in healthy volunteers

Comparison of steady-state pharmacokinetics of two dosage regimens of vancomycin in normal volunteers

P304

237-250

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/PSP4.12279

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Chie Emoto

A Vinks

P577

2018-02-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29446256

http://www.w3.org/2001/XMLSchema#string

P932

5915605

http://www.w3.org/2001/XMLSchema#string